Adasuve’s Extensive REMS Proposal Raises Questions About Whether It Could Work In Practice
Executive Summary
Patient screening to ensure pulmonary risks are mitigated could be difficult in emergency room settings, advisory committee says about inhaled loxapine formulation.
You may also be interested in...
Biotech Stocks and Advisory Committees: No News Is Good News?
FDA has approved six new molecules already in 2012--and five were approved without going to an advisory committee. Meanwhile, FDA has held four advisory committees to review new drug applications, and all four ended in overwhelming "no" votes.
Alexza’s Revised Adasuve REMS Borrows From Risk Management Plan For Zyprexa Relprevv
A resubmitted Risk Evaluation and Mitigation Strategy that proposes to limit use of inhaled loxapine to health care facilities with ready access to advanced airway support borrows from language in the REMS for Lilly’s long-acting intramuscular injection formulation of olanzapine, Alexza’s CEO says.
Where Confusion Reigned Supreme
FDA was forced to skip questions and add others to gain opinions based on the direction of the discussions about the inhaled loxapine formulation. In the process, confusion ensued.